NEW YORK, Nov. 29, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Nivalis Therapeutics, Inc. ("Nivalis" or the
"Company") (NASDAQ: NVLS). Such investors can obtain additional
information and assist the investigation by visiting the firm's
site: www.bgandg.com/nvls.
The investigation concerns whether Nivalis and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On November 28, 2016, Nivalis
announced that its Phase 2 Trial of Cavosonstat was unsuccessful in
meeting its primary endpoint to indicate a benefit in the absolute
change in percent-predicted FEV1 (lung function) or in sweat
chloride reduction at 12 weeks, compared to the placebo. Following
this news, Nivalis stock dropped roughly 59% on intraday trading on
November 29, 2016.
If you are aware of any facts relating to this investigation, or
purchased Nivalis shares, you can assist this investigation by
visiting the firm's site: www.bgandg.com/nvls. You can also contact
Peretz Bronstein or his Investor
Relations Analyst, Yael Hurwitz of
Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
Logo -
http://photos.prnewswire.com/prnh/20161114/439152LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-nivalis-therapeutics-inc-nvls-300370018.html
SOURCE Bronstein, Gewirtz & Grossman, LLC